- Adding maraviroc to standard combined antiretroviral therapy (c-ART) does not improve clinical outcomes among patients presenting with advanced HIV.
- Studies are needed to determine potential value of short-term (6 months) maraviroc use.
Why this matters
- Late diagnosis continues to challenge EU/EE efforts to reduce overall HIV transmission rates.
- Consult WHO consolidated guidelines for testing, including tips for generating demand from patients.
- Data for 409/416 patients analyzed (202 maraviroc; 207 placebo; 85% men; median age, 42 [range, 21-74] years).
- Incidence of severe morbidity (new AIDS-defining event [ADE], serious infections, serious non-ADE):
- Maraviroc: 11.1/100 person-years.
- Placebo: 11.2/100 person-years.
- Adjusted HR, 0.97 (P=.91).
- More serious adverse events seen with maraviroc (11.8/100 person-years) vs placebo (2.9/100 person-years):
- Incidence rate ratio (IRR), 4.00 (95% CI, 1.79-10.10).
- Virologic success rate at week 72 (plasma viral load
- 72.8% with maraviroc vs 78.3% placebo.
- P=.016 for interaction.
- Randomized, placebo-controlled, multicenter study assessing benefit of adding maraviroc to standard, c-ART in persons with advanced HIV.
- Funding: French National Agency for Research on AIDS; ViiV Healthcare.
- No effect-modification analysis.
- Inability to assess time-dependent outcomes.